Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

MITROS, MARK

NPI: 1033111778 · WEXFORD, PA 15090 · Physical Medicine & Rehabilitation Physician · NPI assigned 08/12/2005

$552K
Total Medicaid Paid
10,946
Total Claims
10,065
Beneficiaries
9
Codes Billed
2020-10
First Month
2023-10
Last Month

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2020 623 $29K
2021 4,611 $253K
2022 3,947 $188K
2023 1,765 $82K

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
99214 Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity 6,396 6,272 $224K
95886 1,580 851 $94K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 905 902 $61K
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed 492 491 $52K
95910 347 347 $40K
99204 Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity 367 367 $29K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 416 396 $27K
95911 140 140 $18K
99213 Office or other outpatient visit for the evaluation and management of an established patient, low complexity 303 299 $8K